As of 1/4/2021, Emgality has the best-in-classa commercial access for the preventive treatment of migraine1,2
aBest-in-class commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine. Does not take into consideration any restrictions set forth by individual plans. Data as of 1/2021.
Source: Managed Markets Insight & Technology (MMIT), LLC as of 1/2021 and is subject to change without notice. Please contact the plan or state for the most current information. “Coverage” includes all statuses at or equivalent to Preferred, Covered, Specialty, or Generic for the preventive treatment of migraine. This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employers and employer groups may also offer additional benefit designs, which may be different than described.
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.